Breast Cancer Risk Higher Among Women Who Used Hormonal Contraception

Share this content:
Duration of contraceptive use was also found to impact cancer risk.
Duration of contraceptive use was also found to impact cancer risk.

Breast cancer diagnosis is higher among women who currently use or recently used contemporary hormonal contraceptives than among women who have never used hormonal contraceptives, and this risk increased with longer durations of use, according to a study published in the New England Journal of Medicine.

The research team, led by Lina S. Mørch, PhD, from the Department of Gynecology at the University of Copenhagen, conducted a nationwide prospective cohort study including all women in Denmark between the ages of 15 and 49 years who were not diagnosed with cancer or venous thromboembolism and who never received treatment for infertility. Use of hormonal contraceptives was categorized as current use or recent use (discontinuation within the previous 6 months) or previous use (discontinuation ≥6 months previously). Start of use was the date that the prescription was purchased, and the Danish Cancer Registry was used to identify primary invasive breast cancers.

From January 1, 1995, through December 31, 2012, with a mean follow-up of 10.9 years, a total of 19.6 million person-years and 11,517 incident breast cancer diagnoses occurred in 1,797,932 women between the ages of 15 and 49 years. As compared with women who had never used hormonal contraception, the relative risk [RR] of breast cancer among all current and recent users of hormonal contraception was 1.20 (95% confidence interval [CI]). The risk of breast cancer increased with the duration of use, from 1.09 with ≤1 year of use to 1.38 after ≥10 years of use. After discontinuation of hormonal contraception, the risk of breast cancer was still higher among the women who had used hormonal contraceptives for ≥5 years than among women who had not used hormonal contraceptives.

Risk estimates associated with current or recent use of various oral combination (estrogen-progestin) contraceptives varied between 1.0 and 1.6. Women who currently use or recently used the progestin-only intrauterine device (IUD) also had a higher risk of breast cancer than women who had never used hormonal contraceptives (RR, 1.21). The overall absolute increase in breast cancers diagnosed among current and recent users of any hormonal contraceptive was 13 per 100,000 person-years, or approximately 1 extra breast cancer for every 7,690 women using hormonal contraception for 1 year.

“In this prospective cohort study, the current or recent use of hormonal contraception was associated with a higher risk of breast cancer than the risk among women who had never used hormonal contraceptives, with little evidence of major differences between specific combined oral contraceptives,” the authors concluded. “The risk increased with the duration of use.”

Reference

Mørch LS, Skovlund CW, Hannaford PC, et al. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017 Dec 7;377(23). doi: 10.1056/NEJMoa1700732

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs